BOSTON, MA --(Marketwired - October 20, 2016) - Pieris Pharmaceuticals, Inc . (
The details for each presentation are as follows:
American Association of Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy , Boston Marriott Copley Plaza, Boston, MA, October 20 - 23, 2016
| Presentation Time : Friday, October 21, 2016, 5:15 pm‐7:45 pm, Back Bay room | |
| Presentation: A poster presentation entitled, "Costimulatory T‐cell engagement by PRS‐343, a CD137 (4‐1BB)/HER2 bispecific, leads to tumor growth inhibition and CD8(+) T cell expansion in a humanized mouse model." |
Society of Immunotherapy of Cancer (SITC) , Gaylord National Hotel & Convention Center, National Harbor, Maryland, November 9 - 13, 2016
| Oral Presentation: An oral presentation entitled "PRS-343, a CD137 (4-1BB)/HER2 Bispecific" will be given on Wednesday, November 9, 2016, 11:50 am | |
| Poster Presentation : New Cancer Immunotherapy -- A poster presentation will be presented on Saturday, November 12, 2016, 11:45 am - 1:00 pm and 6:45 pm - 8:00 pm |
About Pieris
Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin ® protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin ® is a registered trademark of Pieris. For more information visit www.pieris.com .
Company Contact: Pieris Pharmaceuticals, Inc. Darlene Deptula-Hicks SVP & Chief Financial Officer 1-603-553-5803 deptula@pieris.com Investor Relations Contact: The Trout Group Thomas Hoffmann 1-646-378-2931 thoffmann@troutgroup.com Media Inquiries: Gretchen Schweitzer +49 172 861 8540 gschweitzer@macbiocom.com